Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China
Shots:
- Aclaris will receive a $5M upfront payment & is eligible to receive up to $91M in development, regulatory & commercialization milestones along with low-to-high single-digit tiered royalties in Greater China
- Under the terms of the agreement, Aclaris granted Pediatrix the exclusive rights to develop, manufacture & commercialize ATI-1777 in China, Macau, Taiwan & Hong Kong whereas Aclaris will retain the rights of ATI-1777 across the world
- ATI-1777 is a soft JAK 1/3 inhibitor with the potential to minimize systemic toxicities in patients with atopic dermatitis
Ref: Globenewswire | Image: Aclaris
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
